FGF-23 Levels before and after Renal Transplantation
- PMID: 20107581
- PMCID: PMC2809417
- DOI: 10.1155/2009/379082
FGF-23 Levels before and after Renal Transplantation
Abstract
Phosphatonin fibroblast growth factor-23 (FGF-23) is involved in phosphate (P) excretion and vitamin D metabolism. Recently, FGF-23 has been suggested to be responsible for the hypophosphatemia and inappropriately low calcitriol levels observed after renal transplantation. We performed a prospective study to investigate FGF-23 levels in patients with end-stage renal disease before and after renal transplantation and their probable association with markers of bone and mineral metabolism. Intact FGF-23 levels were determined before and at 3, 6, and 12 months posttransplantation in 18 renal transplant recipients. Intact parathyroid hormone (iPTH), calcium (Ca), P, 25(OH)VitD, and 1,25(OH)(2)VitD levels were measured at the same time periods. Renal threshold phosphate concentration (TmPO(4)/GFR) was also calculated at 3, 6, and 12 months posttransplantation. The results showed that FGF-23 levels decreased by 89% 3 months posttransplantation (346 +/- 146 versus 37 +/- 9 pg/mL, P < .01) and remained stable throughout the study period. iPTH and P levels also decreased significantly after renal transplantation, while Ca and 1,25(OH)(2)VitD increased. Pretransplantation FGF-23 was significantly correlated with P levels at 3 months posttransplantation (P < .005). In conclusion, FGF-23 levels decrease dramatically after successful renal transplantation. Pre-transplantation FGF-23 correlate with P levels 3 months posttransplantation.
Figures
Similar articles
-
Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients.Transplantation. 2012 Oct 27;94(8):830-6. doi: 10.1097/TP.0b013e318264fc08. Transplantation. 2012. PMID: 23018879
-
Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia.Transplant Proc. 2012 Apr;44(3):657-60. doi: 10.1016/j.transproceed.2011.11.046. Transplant Proc. 2012. PMID: 22483462
-
Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients.Am J Transplant. 2007 May;7(5):1193-200. doi: 10.1111/j.1600-6143.2007.01753.x. Epub 2007 Mar 12. Am J Transplant. 2007. PMID: 17359508 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Mineral and bone disorder after kidney transplantation.World J Transplant. 2015 Dec 24;5(4):231-42. doi: 10.5500/wjt.v5.i4.231. World J Transplant. 2015. PMID: 26722650 Free PMC article. Review.
Cited by
-
Calcineurin inhibitors regulate fibroblast growth factor 23 (FGF23) synthesis.Naunyn Schmiedebergs Arch Pharmacol. 2017 Nov;390(11):1117-1123. doi: 10.1007/s00210-017-1411-2. Epub 2017 Jul 31. Naunyn Schmiedebergs Arch Pharmacol. 2017. PMID: 28761977
-
Potential Role of Bone Metabolism Markers in Kidney Transplant Recipients.Curr Med Chem. 2024;31(19):2809-2820. doi: 10.2174/0109298673250291231121052433. Curr Med Chem. 2024. PMID: 38332694
-
Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.Pediatr Transplant. 2011 Feb;15(1):37-46. doi: 10.1111/j.1399-3046.2010.01405.x. Epub 2010 Oct 8. Pediatr Transplant. 2011. PMID: 20946192 Free PMC article. Review.
-
Early postkidney transplantation hypophosphatemia.J Res Med Sci. 2020 Apr 13;25:36. doi: 10.4103/jrms.JRMS_452_19. eCollection 2020. J Res Med Sci. 2020. PMID: 32582342 Free PMC article.
-
Clinical practice. Fibroblast growth factor (FGF)23: a new hormone.Eur J Pediatr. 2011 May;170(5):545-54. doi: 10.1007/s00431-010-1382-5. Epub 2010 Dec 31. Eur J Pediatr. 2011. PMID: 21193927 Review.
References
-
- Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research. 2004;19(3):429–435. - PubMed
-
- Fukagawa M, Nii-Kono T, Kazama JJ. Role of fibroblast growth factor 23 in health and in chronic kidney disease. Current Opinion in Nephrology and Hypertension. 2005;14(4):325–329. - PubMed
-
- Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary ‘Hyper-Phosphatoninism’? Kidney International. 2006;70(8):1486–1494. - PubMed
-
- Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y. Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. American Journal of Transplantation. 2007;7(5):1193–1200. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous